Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -287.29% is 187% below its 5-year average of -100.14%, near the low end of its 5-year range (-287.29%–-38.28%).
52.69% below its 12-month average of -188.15%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 43.40%.
RETURN ON ASSETS (ROA)
-287.29%
RETURN ON ASSETS (ROA) AVG TTM
-188.15%
RETURN ON ASSETS (ROA) AVG 3Y
-127.49%
RETURN ON ASSETS (ROA) AVG 5Y
-100.14%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.69%
CURRENT VS 3Y AVG
-125.34%
CURRENT VS 5Y AVG
-186.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-790.41%
vs the sector median at left
Surrozen, Inc.
Market Cap
$197.18M
Return on Assets (ROA)
-287.29%
TTM Avg
-188.15%
3Y Avg
-127.49%
5Y Avg
-100.14%
Market Cap
$197.87M
Return on Assets (ROA)
-36.44%
TTM Avg
-34.11%
3Y Avg
-41.19%
5Y Avg
-34.63%
Market Cap
$198.33M
Return on Assets (ROA)
-48.31%
TTM Avg
-30.88%
3Y Avg
-28.11%
5Y Avg
-28.36%
Market Cap
$200.96M
Return on Assets (ROA)
-58.10%
TTM Avg
-37.08%
3Y Avg
-28.02%
5Y Avg
-25.91%
Market Cap
$192.49M
Return on Assets (ROA)
-13.31%
TTM Avg
-10.55%
3Y Avg
-23.05%
5Y Avg
-15.01%
Market Cap
$190.07M
Return on Assets (ROA)
-81.22%
TTM Avg
-42.98%
3Y Avg
-45.19%
5Y Avg
-41.10%
Market Cap
$189.11M
Return on Assets (ROA)
-78.16%
TTM Avg
-23.70%
3Y Avg
-68.26%
5Y Avg
-50.80%
Market Cap
$205.80M
Return on Assets (ROA)
-41.15%
TTM Avg
-52.11%
3Y Avg
-46.68%
5Y Avg
-45.82%
Market Cap
$207.27M
Return on Assets (ROA)
18.34%
TTM Avg
16.50%
3Y Avg
12.68%
5Y Avg
11.55%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Surrozen, Inc. (SRZN) | $197.18M | -287.29% | -188.15% | -127.49% | -100.14% |
| Exagen Inc. (XGN)vs › | $197.87M | -36.44% | -34.11% | -41.19% | -34.63% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | -48.31% | -30.88% | -28.11% | -28.36% |
| Alector, Inc. (ALEC)vs › | $200.96M | -58.10% | -37.08% | -28.02% | -25.91% |
| RxSight, Inc. (RXST)vs › | $192.49M | -13.31% | -10.55% | -23.05% | -15.01% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | -81.22% | -42.98% | -45.19% | -41.10% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -78.16% | -23.70% | -68.26% | -50.80% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -41.15% | -52.11% | -46.68% | -45.82% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 18.34% | 16.50% | 12.68% | 11.55% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
ROA
-287.3%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -245.15% |
| 2024-12-31 | -131.15% |
| 2023-12-31 | -93.41% |
| 2022-12-31 | -40.26% |
| 2021-12-31 | -38.28% |
| 2020-12-31 | -52.57% |
| 2019-12-31 | -57.34% |
